Itraconazole
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
Itraconazole: From Fungal Infections to Pneumocystosis
One-Sentence Summary
Itraconazole is an azole antifungal originally used for fungal infections such as candidiasis, histoplasmosis, aspergillosis, blastomycosis and sporotrichosis. The TxGNN model predicts it may be effective for pneumocystosis, but the data compiled for this report show 0 registered clinical trials and only 20 publications, none of which directly tests itraconazole as a treatment for pneumocystosis.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Fungal infections (esophageal candidiasis, candidemia, histoplasmosis, aspergillosis, blastomycosis, coccidioidomycosis, sporotrichosis, fusariosis, and others). The Canadian licence records contain no indication text. |
| Predicted New Indication | Pneumocystosis |
| TxGNN Prediction Score | 0.9934 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 3 of 4; cancelled: 1) |
| Number of DINs | 4 (marketed: 3) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data are not available in the data compiled for this report. Based on general knowledge, itraconazole inhibits fungal CYP51 (lanosterol 14-alpha-demethylase). This blocks ergosterol synthesis and disrupts the fungal cell membrane.
This mechanism raises doubts about the prediction. Pneumocystis jirovecii has little or no ergosterol in its membrane and relies mainly on cholesterol and other sterols. An azole is therefore not expected to act directly against it. The very high TxGNN score most likely reflects network proximity to other antifungal indications rather than a validated mechanism.
The literature signal appears to come from itraconazole’s use in broad antifungal prophylaxis for immunocompromised patients, such as those with HIV, transplants or febrile neutropenia. In these settings, Pneumocystis prophylaxis is usually given by other agents, typically trimethoprim-sulfamethoxazole. The link to the original indications is therefore weak, and the prediction should be treated as a hypothesis only.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
The publications retrieved are mostly reviews and case series about opportunistic infections in immunocompromised patients. None demonstrates that itraconazole treats pneumocystosis. The table lists the most relevant ones.
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 11737382 | 2001 | Randomized, double-blind, placebo-controlled phase III trial | HIV Medicine | Itraconazole capsules tested for preventing deep fungal infections in HIV-infected, immunodeficient patients. This is general antifungal prophylaxis, not pneumocystosis-specific. |
| 21973267 | 2011 | Review | Clinical Pharmacokinetics | Penetration of antifungal and other anti-infective agents into pulmonary epithelial lining fluid. |
| 21418688 | 2010 | Review | BMJ Clinical Evidence | Primary and secondary prophylaxis of opportunistic infections in HIV. |
| 15250025 | 2004 | Review | Clinical Infectious Diseases | Antimicrobial prophylaxis in febrile neutropenia. Trimethoprim-sulfamethoxazole is highly effective against Pneumocystis pneumonia. |
| 8397916 | 1993 | Review | Current Clinical Topics in Infectious Diseases | Prophylaxis and treatment of infection in bone marrow transplant recipients. |
| 8016481 | 1993 | Review | Seminars in Respiratory Infections | Infection after lung transplantation. |
| 2121456 | 1990 | Review | Drugs | Therapy and prophylaxis of systemic protozoan infections, including Pneumocystis carinii. |
| 26036497 | 2015 | Cohort | Transplantation Proceedings | Single-centre experience of invasive fungal infections after kidney transplantation. |
| 2233233 | 1990 | Case series | Medicine | Disseminated histoplasmosis in AIDS: clinical findings, diagnosis and treatment. |
| 36891307 | 2023 | Case report and review | Frontiers in Immunology | Talaromyces marneffei and Pneumocystis jirovecii coinfection in a child with a STAT1 mutation. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02495988 | ODAN ITRACONAZOLE | Not listed | Not listed |
| 02047454 | SPORANOX | Not listed | Not listed |
| 02484315 | JAMP ITRACONAZOLE ORAL SOLUTION | Oral solution (from product name) | Not listed |
| 02462559 | MINT-ITRACONAZOLE | Not listed | Not listed |
Safety Considerations
- Contraindications suggested by the knowledge graph (these come from drug-disease relationships, not from package insert text):
- Cardiac: long QT syndrome (including familial), torsades de pointes, congestive heart failure, heart failure, cardiomyopathy, hypertrophic cardiomyopathy, myocardial ischemia, coronary artery disease, heart valve disease.
- Liver and kidney: liver disease, drug-induced liver injury, kidney disease, impaired renal function.
- Other: chronic obstructive pulmonary disease, peripheral neuropathy, hearing loss, vision disorders.
- The graph also lists several metabolic and other conditions, including potassium deficiency, hypercalcaemia and achlorhydria.
- Drug Interactions: 100 interactions were recorded. The major ones are:
- Loperamide
- Triamcinolone
- Budesonide
- Moderate interactions include:
- Acid-reducing agents (famotidine, ranitidine, cimetidine, omeprazole, rabeprazole)
- Corticosteroids (hydrocortisone, dexamethasone, betamethasone)
- Alosetron
- Aprepitant
- Minor interactions include metformin, pioglitazone, chlorpropamide and amphotericin B.
Package insert warnings and contraindications were not available in the data compiled for this report. Please refer to the Health Canada package insert.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The TxGNN score is high (0.9934), but the evidence is at L4: there are no registered trials and no study directly supports itraconazole for pneumocystosis.
- Pneumocystis has little or no ergosterol, so the azole mechanism is not expected to work. The score likely reflects network proximity rather than real activity.
- Established agents such as trimethoprim-sulfamethoxazole already cover prophylaxis and treatment.
To proceed, the following is needed:
- Preclinical data (in vitro or animal models) showing activity of itraconazole against Pneumocystis.
- A mechanistic rationale that explains activity without ergosterol dependence.
- Package insert warnings and contraindications from Health Canada, which are currently missing and block safety screening.
- Mechanism-of-action data and approved-indication text for the Canadian licences.
- A review of cardiac and hepatic risks and of the major drug interactions, if the project advances.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.